TrialBritish journal of clinical pharmacology2021

First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.

Luc Bergougnan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.